Brooklyn Investment Group Raises Stake in Johnson & Johnson (NYSE:JNJ)

Brooklyn Investment Group raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 33.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,457 shares of the company's stock after purchasing an additional 4,099 shares during the quarter. Johnson & Johnson accounts for about 0.7% of Brooklyn Investment Group's portfolio, making the stock its 26th biggest position. Brooklyn Investment Group's holdings in Johnson & Johnson were worth $2,380,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of JNJ. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock worth $25,000 after acquiring an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth about $31,000. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after buying an additional 91 shares in the last quarter. Finally, Activest Wealth Management bought a new position in shares of Johnson & Johnson in the third quarter valued at approximately $40,000. Institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 16th. Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a report on Wednesday, November 6th. Cantor Fitzgerald reissued an "overweight" rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, StockNews.com lowered Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday. Seven investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average price target of $174.29.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.74 during midday trading on Friday, reaching $147.03. 10,678,393 shares of the stock were exchanged, compared to its average volume of 6,880,262. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The firm has a market cap of $353.99 billion, a PE ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The company's fifty day moving average is $148.51 and its 200-day moving average is $156.03.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.37%. Johnson & Johnson's dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.